Consolidated Statements of Cash Flows - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net income (loss)		$ (57,390)	$ (112,210)	$ (947,597)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		681,808	591,048	30,838
Amortization of capitalized software developed for sale		3,509	1,326
Accretion and changes in estimate, net		25,276	11,644	15,823
Equity compensation		95,730	59,016	1,701
Deferred income tax expense (benefit)		(49,060)	(50,114)	(143,822)
Amortization of debt discount and issuance costs		31,284	32,532	2,235
Loss on extinguishment of debt		3,885	8,924
(Gain) loss on other investments				(15,881)
Non-cash lease expense		26,648	29,114
Gain on sale of businesses			(59,143)
Goodwill impairment charge				561,164
Loss from Equity Method Investment in the Joint Venture				380,713
Tax receivable agreement charges				164,633
Other, net		17,658	8,257	(1,110)
Changes in operating assets and liabilities:
Accounts receivable, net		12,295	(6,064)	(21,211)
Contract assets, net		(26,114)	158
Prepaid expenses and other assets		(82,507)	(87,540)	(6,219)
Accounts payable		34,825	(21,407)	7,532
Accrued expenses and other liabilities		(61,032)	14,178	(195,207)
Deferred revenue		40,063	166,477	11,304
Due to the Joint Venture, net				1,176
Net cash provided by (used in) operating activities		696,878	586,196	(153,928)
Cash flows from investing activities:
Capitalized expenditures		(276,276)	(246,381)	(13,002)
Acquisitions, net of cash acquired			(439,483)	330,667
Proceeds from sale of businesses			115,733
Investment in the Joint Venture				(610,784)
Investment in debt and equity securities of the Joint Venture				(278,875)
Other, net		(663)	2,099	7,332
Net cash provided by (used in) investing activities		(276,939)	(568,032)	(564,662)
Cash flows from financing activities:
Payments on Term Loan Facility		(180,000)	(315,000)
Payments under tax receivable agreements		(21,537)	(20,691)
Receipts (payments) on derivative instruments		(22,709)	(29,538)	(890)
Employee tax withholding on vesting of equity compensation awards		(37,751)	(4,108)
Payments on deferred financing obligations		(10,991)	(19,519)
Payment of senior amortizing notes		(16,384)	(15,636)	(11,094)
Proceeds from exercise of equity awards		8,933	17,514
Payments on Revolving Facility			(250,000)
Proceeds from Revolving Facility				250,000
Proceeds from issuance of Senior Notes			325,000
Proceeds from initial public offering, net of issuance costs				608,679
Proceeds from issuance of equity component of tangible equity units, net of issuance costs				232,929
Proceeds from issuance of debt component of tangible equity units				47,367
Other, net		(468)	(6,800)	(1,421)
Net cash provided by (used in) financing activities		(280,907)	(318,778)	1,125,570
Effect of exchange rate changes on cash and cash equivalents		165	3,310	16
Net increase (decrease) in cash and cash equivalents		139,197	(297,304)	406,996
Cash and cash equivalents at beginning of period		113,101	410,405	3,409
Cash and cash equivalents at end of period		252,298	113,101	410,405
Supplemental disclosures of cash flow information
Cash paid for interest		223,658	240,232	265,633
Cash paid for income taxes		7,983	11,169	(714)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows		36,729	41,262
Financing cash flows		468	642
Issuance of common stock upon exercise of equity awards:
Investment in the Joint Venture				5,077
Dividend receivable				(5,077)
Change Healthcare Inc. portion of the Joint Venture equity transactions:
Investment in the Joint Venture				13,902
Additional paid in capital				(11,133)
Accumulated other comprehensive income				(2,769)
Capitalized Expenditures:
Property and equipment, net		9,130	2,662	5,295
Other noncurrent assets, net		30,756	25,338	14,169
Intangible assets, net		2,725	1,491	2,855
Accounts payable		(24,533)	(11,040)	(9,843)
Accrued expenses		(18,078)	(18,452)	$ (12,476)
Right-of-use assets obtained in exchange for lease liabilities
Operating Leases	[1]	$ 3,325	16,185
Finance Leases	[1]		$ 363

[1] Amounts exclude the impact of adopting ASC 842. See Note 2, Significant Accounting Policies.